Media Coverage

Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine.

As Quest Diagnostics President and CEO Jim Davis noted at the 44th Annual JP Morgan Healthcare Conference last week, the RESULTS Act still needed to go through markup in a House subcommittee, then receive consideration in the Senate, undergo a technical feasibility assessment by the US Centers for Medicare and Medicaid Services, and then receive a score from the Congressional Budget Office. "That's a lot of work to be done in 18 days," he said. Davis added, however, that he is "optimistic that the RESULTS Act will get passed in 2026" and that Congress will pass a temporary delay as long as the RESULTS Act is making progress toward passage.

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health. The lab giants, in separate agreements announced Thursday, Jan. 8, have added Visby Medical’s newly approved, fully at-home PCR test for sexually transmitted infections to their lineup of direct-to-consumer women’s health offerings.

Southfield, Mich.-based Corewell Health and Secaucus, N.J.-based Quest Diagnostics have finalized a lab joint venture and hospital lab management agreement. Quest Diagnostics and Corewell Health’s existing labs will continue to provide services to the joint venture until a 100,000-square-foot centralized lab at the Corewell Health Southfield Center opens in the first quarter of 2027. The new facility will feature advanced diagnostic technologies, including high-throughput molecular testing and automated microbiology.

Quest Diagnostics handles the blood and other biological specimens of one in three Americans every year — and much of the testing, processing and logistics of those samples runs largely unseen through Tampa Bay.